ClinicalTrials.gg
RecruitingNCT07295821NSCLCUpdated Oct 28, 2026

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

A Phase 2 interventional study of Osimertinib in Lung Cancer, sponsored by AstraZeneca. Recruiting at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 28, 2026Site recruiting status changedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing osimertinib in Lung Neoplasms — 10 open to participants now, 18 under way, 2 of them phase 3. osimertinib · Lung Neoplasms.

Planned enrollment
13th of 30
60 · median 52
Started
2026
with 3 others
Phase 2
16 of 30
5 open now
Primary completion
2029-05
later than 16 of 17 live
Registered
27th of 30
by date
Lead sponsor
10 of 30
AstraZeneca

Among the 30 studies testing osimertinib in Lung Neoplasms, this one is the 13th largest by planned enrollment, is one of 4 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 16 of the 17 other live ones, and was the 27th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 30 studies testing osimertinib in Lung Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing osimertinib in Lung Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent RT and maintenance osimertinib in chemotherapy ineligible or refusal adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).

Read the detailed description

Study details include:

  • The study duration will be approximately 13 months for recruitment and 2 years of follow up from the last patient's initiation into the study.
  • The induction treatment with osimertinib will be up to12 weeks, followed by 6 weeks of RT treatment and osimertinib maintenance treatment until disease progression or death.
  • The visit frequency will be once after 12 weeks during the induction treatment period, every 3 weeks during the RT period (daily visits for RT), and every 12 weeks during the osimertinib maintenance treatment period.
03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • NSCLC
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the form.
  2. Participants with documented NSCLC of predominantly nonsquamous, squamous, and adenosquamous pathology who present with locally advanced, unresectable (Stage III, according to Version 8 of the IASLC Staging Manual in Thoracic Oncology) disease. It is recommended but not required that except for overt cT4 disease, nodal status N2, or N3 should have been proven by , via endobronchial ultrasound, mediastinoscopy, thoracoscopy, or in absence of biopsy, should have been confirmed with whole body contrast-enhanced CT.
  3. Participants who had recurred from Stage I/II/III after complete surgery or had gross incomplete resections can be included if they didn't receive treatment with any chemotherapy, radiation therapy, immunotherapy, targeted therapy, or agents.
  4. Participants with availability of the EGFRm test results confirming that the tumor harbors 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo T790M
  5. of 0, 1 or 2 with no deterioration over the previous 2 weeks prior to baseline at screening and prior to first dose.
  6. Participants who are eligible for and planning to undergo RT treatment per physician assessment.
  7. Participant refusal or ineligible for chemotherapy per physician assessment.
  8. Minimum of > 12 weeks at Day 1.
  9. At least one lesion that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT or MRI and is suitable for accurate repeated measurements.
  10. Capable of giving signed informed consent as described which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria

  1. Any presence of small cell and mixed small-cell and non-small cell histology.
  2. Past medical history of ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require ), or drug-induced ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the participant to participate in the trial or which would jeopardize compliance with the protocol, or active infection.
  4. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.
  5. History of another primary except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease. Patients who have received RT with overlapping fields (eg, cured breast cancer) should be excluded.
  6. Patient meets any of the following cardiac criteria: Mean resting > 470 msec, obtained from 3 ECGs, using the screening clinic machine-derived QTc value. Hypomagnesaemia and hypocalcaemia are acceptable at screening if ≤ Grade 1. Values > Grade 1 for magnesium or calcium should be corrected to ≤ Grade 1 prior to first dose, with documentation of the correction attempt.
  7. Inadequate bone marrow reserve or organ function.
  8. Patients who are currently taking strong inducers and cannot discontinue them at least 3 weeks before the first study dose must be excluded. This is because strong CYP3A4 inducers can decrease the exposure of osimertinib.
  9. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy.
  10. Prior treatment with any chemotherapy, radiation therapy, immunotherapy, targeted therapy, or agents for locally advanced, unresectable Stage III NSCLC. Prior surgical resection (ie, Stage I, II, or III) with no systemic treatment with residual disease or a recurrence is permitted.
  11. Prior exposure to EGFR-TKI therapy.
  12. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  13. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks.
  14. History of to active or inactive of osimertinib or drugs with a similar chemical structure or class to osimertinib.
  15. History of hypersensitivity to active or inactive excipients of RT.
  16. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  17. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  18. Previous enrolment in the present study. Rescreening of individuals who were screen failures is allowed.
  19. For females only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding.
  20. Patients should refrain from breastfeeding from enrolment throughout the study and until 6 weeks after last dose of study intervention.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Osimertinib as Induction Therapy Prior to Radiotherapy and Maintenance

    80 mg Osimertinib QD

    Drug: Osimertinib

Interventions

06

What researchers measure

Primary outcomes

  1. PFS (Progression-Free Survival)

    PFS is defined as the time from date of first dose until progression per RECIST 1.1 as assessed by the investigator at the local site, or death due to any cause.

    Time frame: Assessed from date of first dose to progression (up to a maximum of approximately 2 years)

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR is defined as the percentage of subjects who have a best overall response of CR or PR or SD (at 12 weeks) as determined by the investigator at the local site per RECIST 1.1.

    Time frame: Assessed during the induction phase of the study, scans are carried out at week 12 (plus or minus visit window).

  2. Overall Survival (OS)

    OS is defined as time from date of first dose until the date of death due to any cause.

    Time frame: Assessed from first dose to end of study or death (up to a maximum of approximately 2 years)

Other outcomes

  1. AEs

    To assess the safety of osimertinib used as an induction therapy prior to RT and maintenance osimertinib treatment by assessment of AEs in patients with unresectable EGFRm NSCLC

    Time frame: From signing ICF to 28 days after last dose or end of study (up to a maximum of approximately 2 years)

07

Study locations

18 of 20 sites recruiting
  • Research Site
    Beijing, 100021, China
    Recruiting
  • Research Site
    Beijing, 100730, China
    Recruiting
  • Research Site
    Changchun, 130021, China
    Recruiting
  • Research Site
    Changsha, 410013, China
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Recruiting
  • Research Site
    Foshan, 528000, China
    Recruiting
  • Research Site
    Fuzhou, 350011, China
    Recruiting
  • Research Site
    Guangzhou, 510060, China
    Recruiting
  • Research Site
    Guangzhou, 510100, China
    Recruiting
  • Research Site
    Harbin, 150081, China
    Recruiting
  • Research Site
    Hefei, 230031, China
    Not yet recruiting
  • Research Site
    Jinan, 250021, China
    Recruiting
  • Research Site
    Kunming, 650118, China
    Recruiting
  • Research Site
    Nanchang, 330006, China
    Recruiting
  • Research Site
    Qingdao, 110016, China
    Not yet recruiting
  • Research Site
    Shanghai, 200120, China
    Recruiting
  • Research Site
    Shanghai, 200433, China
    Recruiting
  • Research Site
    Taiyuan, 030000, China
    Recruiting
  • Research Site
    Wenzhou, 325000, China
    Recruiting
  • Research Site
    Xuzhou, 221000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trails via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrails.pharmacm.com/ST/Submission/Disclosure. Indicates that AZ accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrails.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in approved sponsored tool. Signed Data Sharing Agreement(non-negotiable contract for data accessors)must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MES to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrails.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2029, 37 months after the start.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 37 months is close to that.

Counting every sponsor, half of 364 studies reached it within 65 months; a quarter within 34 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 22, 2025
StartActual
Apr 1, 2026
Primary completionEst.
May 30, 2029
CompletionEst.
May 30, 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites changed recruiting status (14 now recruiting)
Show 14 sites
  • Research Site · Beijing, ChinaNot yet recruiting→Recruiting
  • Research Site · Changchun, ChinaNot yet recruiting→Recruiting
  • Research Site · Changsha, ChinaNot yet recruiting→Recruiting
  • Research Site · Chengdu, ChinaNot yet recruiting→Recruiting
  • Research Site · Foshan, ChinaNot yet recruiting→Recruiting
  • Research Site · Fuzhou, ChinaNot yet recruiting→Recruiting
  • Research Site · Guangzhou, ChinaNot yet recruiting→Recruiting
  • Research Site · Harbin, ChinaNot yet recruiting→Recruiting
  • Research Site · Jinan, ChinaNot yet recruiting→Recruiting
  • Research Site · Kunming, ChinaNot yet recruiting→Recruiting
  • Research Site · Nanchang, ChinaNot yet recruiting→Recruiting
  • Research Site · Shanghai, ChinaNot yet recruiting→Recruiting
  • Research Site · Taiyuan, ChinaNot yet recruiting→Recruiting
  • Research Site · Xuzhou, ChinaNot yet recruiting→Recruiting
Oct 28, 2026
Eligibility
11 exclusion criteria edited, 4 added
What changed in the criteria
Exclusion criteria
  • ChangedBefore Past medical history of ILD, drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.Now Past medical history of ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  • EditedPatient meets any of the following cardiac criteria: Mean resting QTc > 470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value. Hypomagnesaemia and hypocalcaemia are acceptable at screening if ≤ CTCAE Grade 1. Values > Grade 1 for magnesium or calcium should be corrected to ≤ Grade 1 prior to first dose, with documentation of the correction attempt.
  • AddedPatients who are currently taking strong CYP3A4 inducers and cannot discontinue them at least 3 weeks before the first study dose must be excluded. This is because strong CYP3A4 inducers can decrease the exposure of osimertinib.
  • AddedAny unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy.
  • EditedAny unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy. Prior treatment with any chemotherapy, radiation therapy, immunotherapy, targeted therapy, or investigational agents for locally advanced, unresectable Stage III NSCLC. Prior surgical resection (ie, Stage I, II, or III) with no systemic treatment with residual disease or a recurrence is permitted.
  • AddedPrior exposure to EGFR-TKI therapy.
  • Edited11 Prior exposure to EGFR-TKI therapy. 12 Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  • Edited13 Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks.
  • Edited14 History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.
  • AddedHistory of hypersensitivity to active or inactive excipients of RT.
  • Edited15 History of hypersensitivity to active or inactive excipients of RT. 16 Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  • Edited17 Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  • Edited18 Previous enrolment in the present study. Rescreening of individuals who were screen failures is allowed.
  • Edited19 For females only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding.
  • Edited20 Patients should refrain from breastfeeding from enrolment throughout the study and until 6 weeks after last dose of study intervention.
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    16 sites changed recruiting status (16 now recruiting)
    Show 16 sites
    • Research Site · Beijing, ChinaNot yet recruiting→Recruiting
    • Research Site · Beijing, ChinaNot yet recruiting→Recruiting
    • Research Site · Changchun, ChinaNot yet recruiting→Recruiting
    • Research Site · Changsha, ChinaNot yet recruiting→Recruiting
    • Research Site · Chengdu, ChinaNot yet recruiting→Recruiting
    • Research Site · Foshan, ChinaNot yet recruiting→Recruiting
    • Research Site · Fuzhou, ChinaNot yet recruiting→Recruiting
    • Research Site · Guangzhou, ChinaNot yet recruiting→Recruiting
    • Research Site · Harbin, ChinaNot yet recruiting→Recruiting
    • Research Site · Jinan, ChinaNot yet recruiting→Recruiting
    • Research Site · Kunming, ChinaNot yet recruiting→Recruiting
    • Research Site · Nanchang, ChinaNot yet recruiting→Recruiting
    • Research Site · Shanghai, ChinaNot yet recruiting→Recruiting
    • Research Site · Shanghai, ChinaNot yet recruiting→Recruiting
    • Research Site · Taiyuan, ChinaNot yet recruiting→Recruiting
    • Research Site · Xuzhou, ChinaNot yet recruiting→Recruiting
    Eligibility 11 exclusion criteria edited, 4 added
    What changed in the criteria
    Exclusion criteria
    • ChangedBefore Past medical history of ILD, drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.Now Past medical history of ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
    • EditedPatient meets any of the following cardiac criteria: Mean resting QTc > 470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value. Hypomagnesaemia and hypocalcaemia are acceptable at screening if ≤ CTCAE Grade 1. Values > Grade 1 for magnesium or calcium should be corrected to ≤ Grade 1 prior to first dose, with documentation of the correction attempt.
    • AddedPatients who are currently taking strong CYP3A4 inducers and cannot discontinue them at least 3 weeks before the first study dose must be excluded. This is because strong CYP3A4 inducers can decrease the exposure of osimertinib.
    • AddedAny unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy.
    • EditedAny unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy. Prior treatment with any chemotherapy, radiation therapy, immunotherapy, targeted therapy, or investigational agents for locally advanced, unresectable Stage III NSCLC. Prior surgical resection (ie, Stage I, II, or III) with no systemic treatment with residual disease or a recurrence is permitted.
    • AddedPrior exposure to EGFR-TKI therapy.
    • Edited11 Prior exposure to EGFR-TKI therapy. 12 Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
    • Edited13 Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks.
    • Edited14 History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.
    • AddedHistory of hypersensitivity to active or inactive excipients of RT.
    • Edited15 History of hypersensitivity to active or inactive excipients of RT. 16 Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
    • Edited17 Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
    • Edited18 Previous enrolment in the present study. Rescreening of individuals who were screen failures is allowed.
    • Edited19 For females only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding.
    • Edited20 Patients should refrain from breastfeeding from enrolment throughout the study and until 6 weeks after last dose of study intervention.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07295821
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Apr 1, 2026
Primary completion
May 30, 2029 (estimated)
Completion
May 30, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion